Perrigo Reaches Year Anniversary For First OTC Brand Switch With Sixth Packaging Approval
Latest FDA approval for mometasone furoate, 50-mcg metered spray, is for three 144-spray containers. Nasonex 24HR Allergy is Perrigo’s first OTC switch of national brand and first mometasone furoate offered nonprescription in US.
You may also be interested in...
Perrigo’s First National Brand, Nasonex OTC Switch, Will Have Familiar Buzz In Advertising
Firm to promote Nasonex 24HR Allergy nasal spray with cartoon bee familiar with brand’s marketing as an Rx product. It doesn't anticipate receiving OTC market exclusivity along with approval of first OTC mometasone furoate product in US.
Perrigo Prioritizes Innovating First After Following OTC Brands To Market
Perrigo’s "national brand better" approach includes adding "better" value to generic equivalents that branded aren't offering, says President and CEO Murray Kessler. Prevacid 24 HR acquisition puts Perrigo at top of 15-mg lansoprazole PPI brand sales as well as in the generics market.
Omega Marks The Alpha Of Perrigo’s OTC Brand Play
The deal expands Perrigo’s distribution footprint from less than 10 to more than 40 countries, but also points toward marketing branded OTCs in some of Omega’s European markets. But another growth driver is in its generic OTC wheelhouse – retailers offering more store brand products, says Perrigo CEO Joseph Papa.